Biotechnology

2 Biotech Companies Lead the Race to Develop a Zika Vaccine

2 Biotech Companies Lead the Race to Develop a Zika Vaccine
Image credit: Pixabay
2 min read

Two biotech companies have emerged as frontrunners in the race to develop a vaccine for Zika, a mosquito-borne virus that has affected more than 4,700 live births in Brazil and crept into 32 neighboring countries, according to a report from the World Health Organization.

Inovio Pharmaceuticals, a small Pennsylvania pharmaceuticals company, has positioned itself as one likely contender thanks to its previous work with mosquito-born diseases and its relatively quick turnaround time from concept to testing, according to Fortune.

In the past few months, investors have shown excitement about Inovio’s Zika initiative. Its stocks have surged since the company announced its bid for a vaccine last December.

Since then, Inovio has made strides toward creating a DNA-based vaccine. While the vaccine has only been tested on mice, Inovio’s CEO said the company will begin testing primates within the next few weeks. Human trials, meanwhile, could start as early as the end of the year.

Related: Genetically-Altered Mosquitoes May Be Key to Eradicating Malaria, Study Shows

Bharat Biotech, a biotech firm based in Hyderabad, India, has been developing a Zika vaccine for more than a year. The firm started working on the virus, along with other mosquito-born illnesses, in November 2014 and has two possible vaccines -- a DNA-based version and a more traditional one that contains an inactive strain of the virus -- ready for pre-clinical trials, the company’s CEO told Reuters

While vaccines, which require high investment and have low success rates, are risky investment bets for pharmaceutical companies, the race for a Zika vaccine is (thankfully) becoming a crowded one. Major pharmaceuticals, including France’s Sanofi Pasteur, Japan’s Takeda Pharmaceutical and U.S. pharma-giant GlaxoSmith Kline, are also exploring vaccines.

Despite these companies’ efforts, a Zika vaccine may still be years away.

Related: Why More Startups Are Paying Attention to What They Learned in Bio

More from Entrepreneur

David provides constructive insight to help businesses focus on their company growth, build brand awareness and know when and how to raise money.
Book Your Session

In as little as seven months, the Entrepreneur Authors program will turn your ideas and expertise into a professionally presented book.
Apply Now

Are paying too much for business insurance? Do you have critical gaps in your coverage? Trust Entrepreneur to help you find out.
Get Your Quote Now

Latest on Entrepreneur

My Queue

There are no Videos in your queue.

Click on the Add to next to any video to save to your queue.

There are no Articles in your queue.

Click on the Add to next to any article to save to your queue.

There are no Podcasts in your queue.

Click on the Add to next to any podcast episode to save to your queue.

You're not following any authors.

Click the Follow button on any author page to keep up with the latest content from your favorite authors.